Abstract: OBJECTIVE To investigate the effect of simvastatin on high sensitivity C reactive protein(hs-CRP), human matrix metalloproteinase-9(MMP-9) and transforming growth factor-β1 (TGF-β1) in patients with coronary heart disease. METHODS The 60 patients with coronary heart disease were selected and randomly divided into observation group and control group with 30 cases in each. The two groups of patients were given conventional two grade prevention drug treatment. The patients of observation group were treated with simvastatin 40 mg·d^-1 orally, while the control group with simvastatin 20 mg·d^-1. After 6 months’ treatment, hs-CRP, MMP-9, TGF-β1 and low density lipoprotein cholesterol (LDL-C) levels of the two groups were compared. RESULTS After the treatment, LDL-C, MMP-9 and hs-CRP concentrations of the two groups were decreased significantly (P<0.05). The difference of TGF-β1 levels before and after the treatment was not statistically significant (P>0.05). The LDL-C, MMP-9 and hs-CRP levels of the observation group were significantly lower than the control group (P<0.05). The difference of TGF-β1 levels between the two groups was not statistically significant (P>0.05). The LDL-C compliance rate and strengthening compliance rate of the observation group was 93.33% and 73.33%, which were significantly higher than the control group(66.67%, 33.33%, P<0.05). CONCLUSION Long-term administration of simvastatin can reduce blood lipid and inflammatory factors level. The effect of intensive lipid-lowering therapy is better.